Skip to content

Sense of Coherence and Empowerment at Patients With MUPS

Sense of Coherence and Empowerment at Patients With Medically Unexplained Physical Symptoms in General Practice

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05121922
Enrollment
30
Registered
2021-11-16
Start date
2021-08-15
Completion date
2025-06-30
Last updated
2022-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medically Unexplained Symptoms, Sense of Coherence

Brief summary

This is a study on Metacognitive therapy in general practice in Norway. The intervention is a small pilot study to examine whether Metacognitive therapy is feasible in an ordinary general practice. Will the physicians be capable to learn and provide the therapy method for their patients with MUPS and is is possible to implement this in an ordinary general practice routine? Both physicians and their patients will be asked to respond to a questionnaire on perceived utility of the treatment.

Detailed description

Metacognitive therapy is different from Cognitive therapy in the sense that it adresses the individual's attention towards potential worries and threats and also the management performed by the patient to avoid these. Also the individual's capacity to produce empowerment to manage these threats are of interest in the talks with the health care provider. - In this study, General Practitioners with specific training in Metacognitive therapy will be asked to recruit 2-3 patients with Medically Unexplained Physical Symptoms each and invite them to a series of Metacognitive Therapy. The patients and physicians will then provide their assessments of the treatment on a number of questionnaires. To explore the Sense of coherence and Empowerment among patients with Medically Unexplained Symptoms, the physicians will be asked to recruit six patients each to respond to a questionnaire.

Interventions

Psychological treatment provided by the patient's regular general practitioner

Sponsors

University of Oslo
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* MUPS: Medically Unexplained Physical Symptoms * somatic and mental examination sufficiently accomplished * ongoing symptoms * more than three months of disabeling symptoms

Exclusion criteria

* not capable to respond on a written questionnaire in Norwegian

Design outcomes

Primary

MeasureTime frameDescription
Feasibility in daily practiceOne yearThe physicians will record the number of patients that agree to participate and complete the treatment

Secondary

MeasureTime frameDescription
Effect of metacognitive therapyOne yearParticipating patients will respond on The Cognitive Attentional Syndrome Questionnaire (CAS-1) following each treatment session. A reduced score indicates improvement of symptom burden.

Countries

Norway

Contacts

Primary ContactIngunn Leeber, MD
ingunnleeber@gmail.com+47 936 10 535
Backup ContactErik L. Werner, PhD
e.l.werner@medisin.uio.no+47 91768413

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026